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Gábor Nyírő2, Ábel Decmann  1, Erna Pap5, Michaela Luconi  6, Massimo Mannelli6, Edit I. 
Buzás5, Miklós Tóth1, Marco Boscaro3, Attila Patócs2,7 & Peter Igaz  1,2
There is no available blood marker for the preoperative diagnosis of adrenocortical malignancy. 
The objective of this study was to investigate the expression of extracellular vesicle-associated 
microRNAs and their diagnostic potential in plasma samples of patients suffering from adrenocortical 
tumors. Extracellular vesicles were isolated either by using Total Exosome Isolation Kit or by 
differential centrifugation/ultracentrifugation. Preoperative plasma extracellular vesicle samples of 
6 adrenocortical adenomas (ACA) and 6 histologically verified adrenocortical cancer (ACC) were first 
screened by Taqman Human Microarray A-cards. Based on the results of screening, two miRNAs were 
selected and validated by targeted quantitative real-time PCR. The validation cohort included 18 ACAs 
and 16 ACCs. Beside RNA analysis, extracellular vesicle preparations were also assessed by transmission 
electron microscopy, flow cytometry and dynamic light scattering. Significant overexpression of hsa-
miR-101 and hsa-miR-483-5p in ACC relative to ACA samples has been validated. Receiver operator 
characteristics of data revealed dCThsa-miR-483-5p normalized to cel-miR-39 to have the highest diagnostic 
accuracy (area under curve 0.965), the sensitivity and the specifity were 87.5 and 94.44, respectively. 
Extracellular vesicle-associated hsa-miR-483-5p thus appears to be a promising minimally invasive 
biomarker in the preoperative diagnosis of ACC but needs further validation in larger cohorts of 
patients.
Adrenocortical tumors are common in humans, and their prevalence rises with age1. These are mainly repre-
sented by benign adrenocortical adenomas (ACA). The majority of ACA is hormonally inactive and thus clin-
ically indolent, but hormone-producing ACAs secreting cortisol or aldosterone are associated with serious 
morbidity and increased mortality1. In contrast, adrenocortical carcinoma (ACC) is a rare, but aggressive neo-
plasm. The incidence of ACC is about 0.5-2 cases per million people per year2, 3. The prognosis of ACC is poor as 
the estimated 5-year survival ranges from 15 to 30% in advanced stages4. There is no reliable preoperative marker 
for distinguishing ACA from ACC at present. Imaging modalities have considerable limitations5 and biopsy is not 
recommended due to difficulties of histological analysis and fear for tumor spread4. Urinary steroid metabolomics 
is a promising approach for preoperative diagnosis of malignancy, but is not widely available and requires a 24 h 
urine collection6.
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Recent studies have reported significantly altered expression of both tissue and circulating microRNAs (miR-
NAs) in ACC versus ACA7–12. MiRNAs are short (19–24 nucletide long) non-protein coding RNA molecules 
involved in the regulation of gene expression primarily as endogenous mediators of RNA interference13. Beside 
tissue miRNAs, novel studies proved the stable existence of miRNAs in different body fluids14, as well. These 
extracellular miRNAs could serve as minimally invasive biomarkers of malignancy and prognosis in different 
tumors15, 16. In our previous study, we found that circulating miRNAs isolated from whole plasma could serve 
as potential biomarkers for adrenocortical carcinoma10. However, the diagnostic sensitivity and specificity were 
not high enough for clinical applicability10. In the blood plasma, miRNAs are found both in extracellular vesicles 
(EV) (such as microvesicles, exosomes, apoptotic bodies) and in macromolecular complexes with lipoproteins17 
or the Argonaute 2 protein18. The mechanism for cellular miRNA release is only partially understood, but the 
active secretion of miRNA in extracellular vesicles appears to be a regulated process19, and thus, might be directly 
linked to disease pathogenesis. Exosomes represent a major class of extracellular vesicles that are formed via 
the endo-lysosomal pathway and are 40–100 nm in diameter19. Exosomal miRNAs might even be implicated in 
cell-to-cell communication20. Whereas circulating miRNAs isolated from whole plasma include miRNAs released 
due to tissue damage or necrosis21, we hypothesize that miRNAs secreted actively in EVs could be more specific 
as minimally invasive biomarkers. The objective of this study was to investigate the expresssion of EV-associated 
miRNAs and their diagnostic potential in patients with adrenocortical tumors. To the best of our knowledge, this 
is the first study to investigate the biomarker potential of extracellular vesicle-associated microRNAs in adreno-
cortical tumors.
Results
Confirming the nature of isolated extracellular vesicles. We have used both transmission electron 
microscopy and flow cytometry to confirm the presence of EVs in our samples to fulfill the minimal experimental 
requirements for extracellular vesicles22.
Transmission electron microscopy microphotographs taken from EVs confirmed that the EV size and mor-
phology corresponded to those described for exosomes (Fig. 1).
Flow cytometric analysis of EVs isolated by ultracentrifugation confirmed the presence of CD9, CD63, 
CD81 membrane proteins and annexin V cytosolic protein (Fig. 2). In the vesicle preparations isolated by Total 
Exosome Isolation (from plasma) Kit, we could identify CD9, CD81 and annexin V (Fig. 2). The percentage of 
positive beads is presented in Supplementary Information Table S1.
Size distribution of the isolated extracellular vesicles. We have used the dynamic light scattering 
technique to measure the size distribution of extracellular vesicles. The vesicles were isolated from 4 samples by 
Total Exosome Isolation (from plasma) Kit. The Z-average value of the 4 samples is 80.83 ± 19.07 nm in PBS at 
25 °C. The detailed results of the dynamic light scattering are summarized in Table 1. The representative size dis-
tribution of EVs in sample 4 is presented in Fig. 3.
Screening by miRNA expression profiling. To identify differences in circulating EV-associated miRNA 
expression profiles of ACA and ACC patients, 12 samples have been subjected to TaqMan Array Human 
MicroRNA A card analysis (6 ACA and 6 ACC plasma samples). Altogether 377 human miRNA have been eval-
uated. By applying straightforward statistics (described in the Methods section) and Benjamini-Hochberg false 
discovery rate (FDR) correction, we have found no significant differences in miRNA expression between the two 
groups. However, we used TLDA data as an initial screening on a limited number of samples and found that 32 
miRNAs are expressed in all samples of both ACA and ACC groups. We identified no miRNA expressed only in 
ACA or ACC groups, either. By using Fisher’s exact test, we evaluated miRNAs which were not expressed in all 
samples of a group and we found 2 miRNAs showing a tendency being different between ACA and ACC samples: 
Figure 1. Transmission electron microscopic image of human blood plasma EVs isolated by 
ultracentrifugation, washed once and submitted to RNAse digestion.
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hsa-miR-101 and hsa-miR-483–5p. These have been selected for further validation. Hsa-miR-101 was expressed 
in 1 of 6 ACA and 5 of 6 ACC samples, whereas hsa-miR-483-5p in 2 of 6 ACA and in all ACC samples. Raw pro-
filing data are presented in Supplementary Dataset file 1.
miRNA Validation by RT-qPCR. The validation cohort included 18 ACAs and 16 ACCs. The widely used 
synthetic spike-in control RNA cel-miR-39 was applied as reference gene16, 23–25. We have found significant overex-
pression of hsa-miR-101 (Fig. 4a) and hsa-miR-483-5p (Fig. 4b) and in ACC relative to ACA plasma EV samples 
(p < 0.0001 and p < 0.0052, respectively). Raw and normalized qRT-PCR data are presented in Supplementary 
Dataset files 2 and 3.
Diagnostic Performance of miRNA. We have evaluated the potential application of EV-associated miR-
NAs as minimally invasive biomarker candidates of adrenal malignancy by ROC analysis. Both, hsa-miR-101 and 
hsa-miR-483-5p, relative to spike-in control cel-miR-39 have been analyzed by ROC analysis. The dCThsa-miR-483-5p 
relative to cel-miR-39 showed the highest area under curve (AUC) value (0.965). By setting the cutoff point to 
17.25, the sensitivity and the specificity of the test to discriminate ACA and ACC were 87.5 and 94.44, respectively 
(Fig. 5). ROC data of hsa-miR-101 have not yielded promising sensitivity and specificity values. By setting the 
cutoff point to 17.82 the AUC value was 0.766, with 68.75 sensitivity and 83.33 specificity.
miRNA expression analysis in samples prepared by ultracentrifugation. We have evaluated the 
expression of hsa-miR-483-5p in vesicles isolated by ultracentrifugation, as well. The ultracentrifugation proto-
col has been performed on 4 ACA and 4 ACC patients. For data normalisation we used cel-miR-39 as reference 
Figure 2. Flow cytometry detection of surface markers of human platelet free blood plasma extracellular 
vesicles (EVs) conjugated onto latex beads. EVs were isolated either by Total Exosome isolation kit (Life 
Technologies, by Thermo Fisher Scientific, Waltham, MA, USA) (empty histograms with dotted lines) or 
ultracentrifugation at 100,000 g (empty histograms with continuous lines) from three different human plasma 
samples, respectively. Antibody binding to BSA-coated latex beads is shown in gray histograms.
Sample 
Name PDI
Standard 
deviation of PDI
Z-average 
(diameter nm)
Standard deviation 
of Z-average
Intensity mean 
(diameter nm)
Standard deviation 
of Intensity mean)
Sample 1 0.21 0.01 97 1.06 122.9 1.77
Sample 2 0.2 0.01 98.6 0.76 124.1 2.77
Sample 3 0.25 0.01 62.8 0.77 85.9 1.85
Sample 4 0.26 0.01 65 0.3 90.8 2.45
Table 1. Results of dynamic light scattering.
Figure 3. Representative size distribution of EVs isolated by Total Exosome Isolation Kit (Life Technologies, 
by Thermo Fisher Scientific) in sample 4 (Table 1). The y axis shows the intensity percentage of the vesicles, and 
the x axis shows the vesicle diameter (nm). The sizes of the EVs were approximately in the range of 16–255 nm 
(diameter [mean ± SD], 90.08 ± 2.45).
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gene. We have found significanty higher expression of hsa-miR-483-5p in exosomes in ACC relative to ACA 
(p = 0.0221, Fig. 6).
Figure 4. Results of RT-qPCR validation of hsa-miR-101 (a) and hsa-miR-483-5p (b) normalized to the 
housekeeping cel-miR-39, (mean ± SD, **p < 0.01, ***p < 0.001; unpaired t-test; n = 18 ACA, n = 16 ACC.
Figure 5. Receiver operating characteristics (ROC) curve analysis for the dCThsa-miR-4835-p exosomes miRNA 
signature relative to housekeeping cel-miR-39 based on the results obtained from RT-qPCR analysis of ACA 
(n = 18) and ACC (n = 16) plasma exosomes samples.
Figure 6. Results of ultracentrifugation with RT-qPCR of hsa-miR-483-5p normalized to the spike-in control 
cel-miR-39. Results are represented by – dCT (cycle threshold) (mean ± s.d., *p < 0.05; unpaired t-test; n = 4 
ACA, n = 4 ACC).
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Discussion
Recent studies indicated that circulating microRNAs could serve as minimally invasive biomarkers of malignancy 
in different tumors26. In our previous study on unfractionated plasma samples, we have found significant over-
expression of 5 circulating miRNAs (hsa-miR-483-5p, hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210) 
in ACC relative to ACA10. Two further studies on circulating microRNAs in unfractionated serum samples from 
adrenocortical tumor patients have been reported to date8, 9. Overexpressed circulating hsa-miR-483-5p in ACC 
has been confirmed in both, along with overexpressed hsa-miR-34a9 and underexpressed hsa-miR-1958. The sen-
sitivity and specificity values for these circulating microRNAs cannot be regarded as high enough for clinical 
introduction at present. The best results reported by Chabre et al. for circulating hsa-miR-483-5p could only be 
used to differentiate aggressive and non-aggressive ACC8.
Multiple studies demonstrated that miRNA content in actively secreted EVs was quite different from that of 
donor cells20, 27, 28. Therefore, it can be hypothesized that, EVs-associated miRNAs might prove to be more sensi-
tive and specific biomarkers for pathological conditions than EV-free miRNAs or miRNAs from unfractionated 
body fluid samples.
We aimed to investigate the the expression of EV-associated miRNAs and their potential diagnostic applica-
bility in patients suffering from adrenocortical tumors. To the best of our knowledge, our study is the first of this 
kind in these tumors.
The overexpression of hsa-miR-483-5p and hsa-miR-101 in ACC has been confirmed in the validation 
cohort. Showing the highest AUC, specificity and sensitivity values, exosomal hsa-miR-483-5p could be a poten-
tial biomarker of adrenal malignancy using cel-miR-39 as reference gene. The significant overexpression of 
hsa-miR-483-5p relative to cel-miR-39 in ACC has been also confirmed by testing EVs isolated by differential 
ultracentrifugation, confirming the EV-association of this miRNA.
There is no broadly accepted valid reference gene for raw data normalization for circulating miRNA29. The 
small nuclear RNA (snRNA) U6, hsa-miR-16 and the synthetic, exogenous spike-in control cel-miR-39 are the 
most frequently applied reference genes29 in different studies. However, snRNA U6 has a significant interindivid-
ual variability30. In our previous study on plasma samples, we have found that hsa-miR-16 and cel-miR-39 were 
applicable for normalization10. In this study, we have also used cel-miR-39 as reference both for samples isolated 
by the kit and ultracentrifugation16, 23–25. As cel-miR-39 is not included in TLDA cards, it could not be assessed as 
reference in the miRNA screening. Cel-miR-39 can not be considered as a valid biological control, but definitely 
indicates the efficacy of miRNA isolation10.
In order to confirm the results obtained by using Total Exosome Isolation Kit and to fulfill the minimal exper-
imental requirements for EVs, we have isolated EVs also by differential centrifugation/ultracentrifugation, and 
carried out EV analysis by using TEM and flow cytometry, as well22. Ultracentrifugation is considered to be gold 
standard of EV isolation to date31. TEM enabled to evaluate both the size and the morphology of EVs, simulta-
neously32. Using flow cytometry we detected the presence of annexin V, CD9 and CD81 on EVs isolated both by 
ultracentrifugation and the kit used. Annexin V and the tetraspanins CD9, CD63 and CD81 are considered to 
be characteristic for EVs33. We can thus conclude that the preparations that we isolated both by the kit used and 
by differential centrifugation/ultracentrifugation were enriched in EVs. From among the different types of EVs, 
exosomes are the ones that are known to be characterized by the presence of CD63, CD9 and CD81 in their mem-
branes. Thus, we may conclude that our preparations were enriched in exosomes. The size distributon analysis of 
extracellular vesicles also supports the exosomal enrichment of the preparations. However, given that at present 
there are no universal markers to distinguish microvesicles form exosomes, in our conclusions we chose to refer 
to EVs rather than exosomes or microvesicles. It must be noted, however, that the expression of CD9 and CD63 
was higher in the EV samples isolated by ultracentrifugation than by the kit used (CD63 was not detected in EV 
samples isolated by the kit). The plasma sample volumes needed for ultracentrifugation are much higher (3 mL) 
than the volumes needed for isolation by the kit (200 µl), thus the yield is also higher by ultracentrifugation. 
However, the ultracentrifugation-based protocol is very laborious and time-consuming, and not easily applicable 
for clinical purposes. Our aim has been to use a methodology that could be easily used in the clinical setting. 
Given the parallel results of miRNA expression used both protocols, we reckon that the isolation kit can be relia-
bly used, and could be used in the clinical setting to analyze larger sets of samples.
Several studies highlight the relevance of these miRNAs in different physiological and pathological conditions. 
Among these, the overexpression of hsa-miR-483-5p has been described both in tissue and in blood of patients 
suffering from ACC7–9, 34, 35. In a previous study, we demonstrated that the expression of circulating hsa-miR-
483-5p was not influenced by treatments with dexamethasone or adrenocorticotropin confirming that it could be 
potentially used in the preoperative diagnostic of ACC36. Furthermore, circulating hsa-miR-483-5p could repre-
sent not only a diagnostic marker, but a prognostic marker, too, since its expression predicts poor prognosis and 
cancer reccurence8.
To the best of our knowledge, the overexpression of hsa-miR-101 in ACC has not been reported so far. There 
are data on the overexpession of hsa-miR-101 in malignant pheochromocytoma compared to benign tumors37. 
Among others, miR-101 may have tumor suppressor role e.g. in stomach38, colorectal39, prostate40, tumors that is 
not suprising for a miRNA considering their tissue specific action. The same miRNA can be oncogenic or tumor 
suppressor depending on the cellular context41.
In our previous study using total plasma as the source of miRNAs, altogether 5 miRNAs proved to be signif-
icantly overexpressed in ACC samples10. Since only selected miRNAs based on previous studies were included 
without profiling, the number of significantly differentially expressed miRNA in total plasma might be even 
higher. In the present study using EV-associated miRNAs, only two could be validated suggesting a possibly more 
specific, adrenocortical origin of these miRNAs underlining the higher potential of EV-associated miRNAs than 
those isolated from whole plasma.
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In conclusion, our results show that EV-associated miRNAs might be promising candidates to be minimally 
invasive biomarkers of adrenocortical cancer. We have used both high-throughput analysis for screening and 
targeted RT-qPCR for validation to investigate the expression of miRNAs, which seems to be the most appropriate 
method for blood-borne miRNA analysis42. However, the limited sizes of patient cohorts, the lack of standard-
ization of EV isolation, miRNA extraction methods and no generally accepted RNA control for normalization 
makes it difficult to generalize the results of such studies. In this study, we have found high enough sensitivity and 
specificity for potential clinical application, however, further studies on larger numbers of patients are needed to 
prove this assumption.
Materials and Methods
Patients’ samples. Altogether 46 preoperative plasma samples have been collected from patients with ACA 
(n = 24) and ACC (n = 22) at the 2nd Department of Medicine Semmelweis University, Budapest, Hungary, the 
Endocrinology Unit of the Department of Medicine, University of Padua, Italy, the Department of Experimental 
and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, Italy and at the Division of 
Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, 
USA. 6 ACA and 6 ACC samples have been included in the screening cohort, whereas 18 ACA and 16 ACC in 
the validation cohort. The study was approved by the Ethical Committee of the Hungarian Health Council and 
informed consent was obtained from all patients involved. All experiments were performed in accordance with 
relevant guidelines and regulations.
In every operated case, the diagnosis of ACA or ACC was determined by histological examination, whereas 
the diagnosis of ACA in non-operated cases was based on imaging and follow-up by abdominal computed 
tomography. The hormonal profile has been investigated in all cases. Tumor stage in ACC was determined based 
on ENSAT (European Network for the Study of Adrenal Tumors) criteria43. The clinical characteristics of both 
cohorts are summarized in Table 2. Patients did not receive chemo- or radiotherapy before blood collection.
Sample processing and extracellular vesicle isolation. In every case, EDTA-anticoagulated blood 
was taken from patients and processed for plasma isolation instantly after collection. Plasma was gained by cen-
trifuging whole blood at 1000 x g for 10 minutes at 4 °C. All extracted plasma samples were stored at −80 °C until 
further use. No hemolysis was observed under these storage conditions.
We used two different approaches for EV isolation. First, EVs were isolated from 200 µl plasma with Total 
Exosome Isolation (from plasma) Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufac-
turer’s protocol.
As a second approach, we isolated EVs from blood plasma with differential centrifugation/ultracentrifuga-
tion. Cellular components were eliminated with centrifugation (2500xg, room temperature, 15 min), then the 
platelet-free plasma was diluted to 2x with phosphate-buffered saline (PBS), and was filtered through a 0.8 µm 
filter (Merck Life Science, Darmstadt, Germany) by hydrostatic pressure to remove remaining platelets and 
apoptotic bodies. The EVs were pelleted with ultracentrifugation at 100.000xg in an MLA-55 fixed-angle rotor 
(BC-OptimaTM Max-XP, MLA-55, A/D: 8, Beckman Coulter, Brea, CA, USA) for 1 h at 4 °C from 6 mL of 0.8 µm 
filtered and 2x PBS-diluted platelet-free plasma samples. The supernatant was discarded and the pellet was resus-
pended in 90 µl PBS. The solution was treated with Ribonuclease A from bovine pancreas (PN: R6513 by Merck 
Life Science). The RNase treatment was suspended by Ribonuclease Inhibitor Recombinant (PN: R1158-2.5KU 
by Merck Life Science). The solution was washed again with 0.1% Bovine serum albumin (BSA) and ProtectRNA 
RNase Inhibitor 500× Concentrate (PN: R7397 by Merck Life Science) and centrifuged at 100,000xg, 4 °C for 
1 h (BC-OptimaTM Max-XP, MLA-55, A/D: 8, by Beckman Coulter). The solution was treated with 700 µl 
QIAzol Lysis Reagent (ID: 79306, Qiagen GmbH, Hilden, Germany). Samples were stored at −20 °C until further 
processing.
Transmission electron microscopy (TEM). To evaluate EVs isolated by ultracentrifugation, paraformal-
dehyde (4%) in 0.01 M PBS was added onto the pellets for 60 min at room temperature. Following washing with 
PBS, we used 1% OsO4 for 30 minutes (Taab, Aldermaston, Berks, UK) for postfixation. The fixed pellets were 
rinsed with distilled water, then graded ethanol was used for the dehydration of the preparations. We applied 1% 
uranyl-acetate in 50% ethanol for 30 min for block staining, and the preparations were inlayed in Taab 812 (Taab). 
Ultrathin sections were made following the overnight polymerization of blocksat 60 °C. We have used Hitachi 
7100 electron microscope (Hitachi Ltd., Japan) equipped with a Megaview II (lower resolution, Soft Imaging 
System, Germany) digital camera for the analysis of the sections.
Flow cytometry. Direct measurement of (EVs) by flow cytometry is limited because of the small size of 
blood plasma EVs Therefore we have first adsorbed the EVs onto the surface of formaldehyde/sulfate Latex-Beads 
(Molecular Probes, Eugene, OR, USA). In brief, EVs were resuspended in PBS and were loaded onto 3.8 μm 
diameter 4% v/v% beads. Two percent BSA was used as a negative control. Then the samples were incubated 
overnight at 4 °C under agitation (5 × g). EV-coated beads were incubated for 1 hour with 2% BSA, and then 
300 μl 0.9% NaCl solution was added and samples were centrifuged for 10 minutes at 2000xg. The beads were 
resuspended in 200 μl 100 mM glycerol solution and were incubated for 30 minutes at room temperature. CD9 
(FITC, Sigma;#:SAB4700095), CD63 (PE, Sigma;#:SAB4700218), CD81 (FITC, molecular probes;#:A15753) and 
annexin V (FITC, SONY; #:3804530) were investigated. Altogether we have evaluated 6 samples (3 from ultra-
centrifugation and 3 isolated by Total Exosome Isolation (from plasma) Kit. Flow cytometry was perfomed by 
FACSCalibur (BD Biosciences, San Jose, CA, USA). For data analysis we have used FlowJo Software (Tri Star Inc., 
Ashland, OR, USA).
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Size distribution of extracellular vesicles. The size distribution of extracellular-vesicles were charac-
terized by dynamic light scattering (DLS) on a Zetasizer Nano S instrument (Malvern Instruments Ltd, Malvern, 
UK) on 4 samples isolated by Total Exosome Isolation (from plasma) Kit (Thermo Fisher Scientific). From the 
intensity fluctuations of a 633-nm laser light scattered at high angle from the freely moving suspended particles, 
their diffusion constant was obtained. Size distribution was calculated by using the Stokes-Einstein equation 
by the built-in algorithms of the instrument’s software. Z-average values are displayed, which represent the pri-
mary and most stable parameter produced by DLS technique44 and are recommended for quality control reports 
Sample 
number
Tumor 
type Cohort Sex
Age at 
blood 
taking 
(year) Hormonal activity
Ki-67 (%) or 
mitotic index 
(N/10 HPF)
Weiss 
score
ENSAT 
Tumor 
stage
1 ACC Screening F 51 Cortisol 25% 9 1
2 ACC Screening F 62 Subclinical testosterone 5/10 HPF 7 3
3 ACC Screening F 46 Non-secreting 10/10 HPF 6 4
4 ACC Screening M 43 Non-secreting n.d. 6 4
5 ACC Screening F 57 Non-secreting 20–25% 5 4
6 ACC Screening F 36 Cortisol n.d. n.d. 4
7 ACC Validation F 67 Cortisol n.d. n.d. 4
8 ACC Validation F 39 Subclinical cortisol 10% 7 1
9 ACC Validation F 57 Non-secreting n.d. 5 4
10 ACC Validation M 80 Non-secreting n.d. 9 3
11 ACC Validation F 56 Testosterone n.d. 6 2
12 ACC Validation M 53 Non-secreting n.d. 9 3
13 ACC Validation F 31 Cortisol n.d. 6 2
14 ACC Validation F 58 Testosterone 2/10HPF 4 3
15 ACC Validation F 24 Androgens 10% 5 2
16 ACC Validation F 22 Subclinical cortisol and androgens 10% 3 1
17 ACC Validation M 62 Cortisol 30% 7 2
18 ACC Validation M 48 Cortisol 15% 8 3
19 ACC Validation F 38 Cortisol, androgens 70% 8 2
20 ACC Validation F 32 Non-secreting 5% 3 1
21 ACC Validation F 20 Non-secreting 5 3 4
22 ACC Validation M 51 Non-secreting 2% 4
23 ACA Screening F 64 Aldosterone n.d. n.d.
24 ACA Screening F 73 Non-secreting n.d. n.d.
25 ACA Screening F 63 Non-secreting n.d. n.d.
26 ACA Screening F 59 Subclinical cortisol n.d. n.d.
27 ACA Screening F 77 Non-secreting n.d. n.d.
28 ACA Screening F 61 Cortisol n.d. n.d.
29 ACA Validation F 38 Non-secreting n.d. n.d.
30 ACA Validation F 74 Non-secreting n.d. n.d.
31 ACA Validation F 52 Non-secreting n.d. n.d.
32 ACA Validation M 29 Non-secreting n.d. n.d.
33 ACA Validation M 71 Non-secreting n.d. n.d.
34 ACA Validation F 81 Non-secreting n.d. n.d.
35 ACA Validation M 63 Non-secreting n.d. n.d.
36 ACA Validation M 50 Non-secreting n.d. n.d.
37 ACA Validation F 50 Cortisol n.d. n.d.
38 ACA Validation F 69 Cortisol n.d. n.d.
39 ACA Validation F 46 Aldosterone n.d. n.d.
40 ACA Validation M 62 Cortisol n.d. n.d.
41 ACA Validation F 33 Cortisol n.d. n.d.
42 ACA Validation F 35 Non-secreting n.d. n.d.
43 ACA Validation F 65 Non-secreting n.d. n.d.
44 ACA Validation F 54 Non-secreting n.d. n.d.
45 ACA Validation F 66 Non-secreting n.d. n.d.
46 ACA Validation M 68 Non-secreting n.d. n.d.
Table 2. Characteristics of patients. n.d.: no data, HPF: high power field, F: female, M: male.
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(ISO 22412:2008). Z-average value represents a good approximation of hydrodynamic diameter of well dispersed 
particles. Polydispersity index (PDI) is an estimate of the width of the distribution which is calculated from the 
cumulants analysis.
Light scattering was measured at 25 ± 1 °C. Extracellular-vesicles (refractive index: 1.370) were suspended in 
1x sterile phosphate buffer (PBS). The viscosity of PBS at 25 °C was 0.8882 cP and the refractive index was 1.330. 
The sample was equilibrated at 25 °C for 1 min.
miRNA expression profiling. Total RNA was instantly extracted from EVs (previously isolated by Total 
Exosome Isolation (from plasma) Kit) using Total Exosome RNA and Protein Isolation Kit (Thermo Fisher 
Scientific). In the validation cohort, 5 µl of 5 nM Syn-cel-mir-39 miScript miRNA Mimic (Qiagen GmbH) as a 
spike-in control for purification efficiency was added before the addition of Acid-Phenol: Chloroform. The final 
total RNA elute was 50 µl. RNA was stored at -70 °C until further processing.
miRNA expression profiling of EVs was performed altogether on 12 samples (6 ACA and 6 ACC) using 
high-throughput real-time qPCR. The samples were processed strictly following the Megaplex Pools for 
microRNA expression Analysis protocol given by the manufacturer as previously described (PN: 4399721B, 
Thermo Fisher Scietific). In brief, the previously isolated RNA was reverse-transcribed using the TaqMan 
microRNA Reverse Transcription Kit (PN 4366597, Thermo Fisher Scientific) and Megaplex RT primers Human 
Pool A v2.1 (PN: 4399966, Thermo Fisher Scietific) on Proflex Base PCR System (Thermo Fisher Scientific). 
Before the Real-Time PCR reactions, we have run the preamplification reactions of cDNA using TaqMan Preamp 
Master Mix (2x) (PN: 4384266, Thermo Fisher Scietific) and Megaplex PreAmp Primers (10x), Human Pool A 
v2.1 (PN: 4399233, Thermo Fisher Scietific) according to the manufacturer’s instructions. The diluted PreAmp 
product was mixed with TaqMan Universal PCR Master Mix, No AmpErase UNG, 2x (PN: 4324018, Thermo 
Fisher Scietific) and was loaded on TaqMan Array Human MicroRNA Cards v2.0 pool A (PN:4398977, Thermo 
Fisher Scientific) and analysed on QuantStudio 7 Flex Real-Time PCR system (Thermo Fisher Scientific). Each 
sample was assayed with an A card resulting in the analysis of a total of 377 human miRNA.
TLDA raw data analysis, threshold settings and basic statistics were perfomed by Applied Biosystems qPCR 
Analysis Modules on Thermo Fisher Cloud (https://www.thermofisher.com/hu/en/home/cloud.html). Due to 
the lack of cel-miR-39 or other universally accepted reference for circulating miRNA studies on the TaqMan 
Array Human MicroRNA Cards system45, we skipped normalization of raw data applying a certain endogenous 
control gene on screening results, therefore the normalized quant for the reference sample then reflected the 
fold change indicated between the different samples directly. We used ACA samples as Reference Biological 
Group, confidence level was set to 95% and Benjamini-Hochberg false discovery rate correction was applied 
for p values. The maximum allowed CT value was set to 40 and microRNAs showing no amplification until 
cycle 40 were considered as not expressed. We used Fisher’s exact test to compare the prevalance of expression 
of those miRNAs which were detected not in all samples (expressed in more ACC samples compared to ACA 
and vice versa).
Validation of individual miRNAs by quantitative Real-Time PCR. Two miRNAs showing a tendency 
being differently expressed between ACA and ACC samples on TaqMan low density array (TLDA) cards have 
been subjected to validation by RT-qPCR. Among these, hsa-miR-101 (002253) and hsa-miR-483-5p (002338) 
were selected for validation by real-time RT-qPCR on altogether 34 samples (18 ACA and 16 ACC patients). 
Total RNA (5 µl) was reverse transcribed using specific TaqMan microRNA Assays (PN 442795, Thermo Fisher 
Scientific) and the TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific) on Proflex Base 
PCR System (Thermo Fisher Scientific). Quantitative RT-PCR was performed by TaqMan Fast Universal PCR 
Master Mix (2x) (PN: 4352042, Thermo Fisher Scientific) on a 7500 Fast Real-Time PCR system (Thermo Fisher 
Scientific) according to the protocol of manufacturer for TaqMan Small RNA Assays (PN 4364031E, Thermo 
Fisher Scientific) with minor modifications. Samples were run in triplicate. Negative control reactions did not 
include cDNA templates. For the evaluation of the data we used the dCT (CT) method (−dCT values = −[CT 
of target miRNA −CT of internal control miRNA])46 using Microsoft Excel 2010 (Microsoft Corporation, 
Redmond, WA, USA).
RNA isolation from vesicles isolated by ultracentrifugation and quantitative Real-Time 
PCR. In the case of EVs isolated by differential centrifugation/ultracentrifugation, RNA was isolated from 
vesicles (n = 4 ACA, n = 4 ACC) using RNeasy Mini Kit (ID:74104, Qiagen GmbH) and RNeasy MinElute 
Cleanup Kit (ID:74204, Qiagen) according to the manufacturer’s protocol. The analysis of vesicular RNA was 
performed by capillary electrophoresis (Agilent Small RNA Kit (CN:5067-1548) on Agilent 2100 Bioanalyzer, 
Agilent Technologies, Santa Clara, CA, USA). 1 µl RNA in solution was analyzed according to the manufactur-
er’s protocol. The reverse transcription and qRT-PCR was performed as previously described above. 0.5 µl of 
5 nM Syn-cel-miR-39 miScript miRNA Mimic (Qiagen GmbH) was added to the isolated RNA elution during 
reverse transcription. We have evaluated the expression of hsa-miR-483-5p in ACA and ACC patients relative to 
cel-miR-39 as reference.
Statistical analysis. Statistical analysis of high-throughput real-time PCR data and RT-qPCR data was 
performed by GraphPad Prism 7.02 (GraphPad Software, Inc., La Jolla, CA, USA). For the identification of dif-
fentially expressed miRNAs between ACA and ACC groups, Student’s t-test or Mann-Whitney test were used 
depending on the results of Shapiro-Wilk normality test. P-values < 0.05 were considered significant.
To identify miRNA markers applicable for diagnosis, receiver operating characteristics (ROC) analysis was 
performed by GraphPad Prism 7.02.
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